#USA #New York #LOTTE BIOLOGICS #Bio Campus #DCAT Week

LOTTE Biologics Participates in DCAT Week 2026

LOTTE Biologics has announced its participation in the upcoming DCAT Week 2026, scheduled from March 23 to March 26 in New York. This event represents a vital opportunity for the company as it seeks to expand its presence within the global pharmaceutical and biotechnology sectors. DCAT Week is recognized as one of the premier gatherings for industry professionals, offering a platform for networking, collaboration, and the exploration of new business ventures.

A Key Global Gathering

Held annually, DCAT Week gathers pharmaceutical firms and contract development and manufacturing organizations (CDMOs) from around the world to focus on collaborative opportunities and current industry trends. LOTTE Biologics will host multiple sessions at the Lotte New York Palace Hotel, the event's venue, aimed at fostering relationships with potential partners and assessing new business opportunities in the global CDMO market, particularly in North America.

During this week-long event, the company will accentuate the strategic synergies between its two key facilities: the Syracuse Bio Campus in New York and the upcoming Songdo Bio Campus in Incheon, South Korea. This latter facility is projected to reach mechanical completion in August 2026, as part of LOTTE Biologics’ commitment to developing an extensive global manufacturing network.

Expanding Manufacturing Capabilities

Adopting a dual-site model across both the United States and Korea, LOTTE Biologics aims to offer its global partners adaptable and dependable manufacturing solutions. This expansion comes as a response to increasing demand within the biopharmaceutical sector and the growing need for efficient manufacturing processes. The company is excited to illustrate how both campuses can collaboratively accelerate production timelines and improve service offerings to meet customer needs.

In addition, LOTTE Biologics intends to highlight its growing range of service capabilities during DCAT Week. Notably, the company has entered into a strategic partnership with Asimov, a U.S.-based expert in cell line development. This collaboration enables LOTTE Biologics to provide comprehensive services from DNA to drug substance, reducing the overall timeline to an impressive 8.5 months from transfection to drug substance release.

Strengthening Global Competitiveness

A representative from LOTTE Biologics stated, "DCAT Week is a crucial event that unites key decision-makers within the global pharmaceutical and biotechnology industries. Our participation is focused on actively exploring partnership opportunities with potential clients while reinforcing our competitive edge in the global market."

The insights and connections made during this event are paramount for companies like LOTTE Biologics, aiming to navigate and thrive in the rapidly evolving landscape of the life sciences sector. As the company gears up for this pivotal week, it is clear that its efforts are geared towards not only enhancing its manufacturing capabilities but also fostering collaborations that could redefine its future trajectory in the biopharmaceutical industry.

By situating itself within such influential gatherings, LOTTE Biologics is positioned to further solidify its role as a leader in the field, ready to meet the diverse needs of partners locally and globally.